GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » China Biotech Services Holdings Ltd (HKSE:08037) » Definitions » Cyclically Adjusted Revenue per Share

China Biotech Services Holdings (HKSE:08037) Cyclically Adjusted Revenue per Share : HK$0.52 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is China Biotech Services Holdings Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

China Biotech Services Holdings's adjusted revenue per share for the three months ended in Dec. 2023 was HK$0.012. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is HK$0.52 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2025-01-19), China Biotech Services Holdings's current stock price is HK$0.375. China Biotech Services Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was HK$0.52. China Biotech Services Holdings's Cyclically Adjusted PS Ratio of today is 0.72.


China Biotech Services Holdings Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for China Biotech Services Holdings's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Biotech Services Holdings Cyclically Adjusted Revenue per Share Chart

China Biotech Services Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.18 1.22 0.97 1.02 0.52

China Biotech Services Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 0.68 0.59 0.52 -

Competitive Comparison of China Biotech Services Holdings's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, China Biotech Services Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Biotech Services Holdings's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, China Biotech Services Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where China Biotech Services Holdings's Cyclically Adjusted PS Ratio falls into.



China Biotech Services Holdings Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, China Biotech Services Holdings's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.012/117.2957*117.2957
=0.012

Current CPI (Dec. 2023) = 117.2957.

China Biotech Services Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.462 95.749 0.566
201406 0.315 96.409 0.383
201409 0.115 97.948 0.138
201412 -0.146 99.707 -0.172
201503 0.079 99.927 0.093
201506 0.025 99.267 0.030
201509 0.049 99.927 0.058
201512 0.019 102.015 0.022
201603 0.025 102.785 0.029
201606 0.027 101.686 0.031
201609 0.031 102.565 0.035
201612 0.038 103.225 0.043
201703 0.043 103.335 0.049
201706 0.033 103.664 0.037
201709 0.027 103.994 0.030
201712 0.029 104.984 0.032
201803 0.020 105.973 0.022
201806 0.019 106.193 0.021
201809 0.020 106.852 0.022
201812 0.020 107.622 0.022
201903 0.015 108.172 0.016
201906 0.015 109.601 0.016
201909 0.015 110.260 0.016
201912 0.017 110.700 0.018
202003 0.013 110.920 0.014
202006 0.019 110.590 0.020
202009 0.533 107.512 0.582
202012 0.112 109.711 0.120
202103 0.160 111.579 0.168
202106 0.228 111.360 0.240
202109 0.136 109.051 0.146
202112 0.123 112.349 0.128
202203 0.399 113.558 0.412
202206 0.314 113.448 0.325
202209 0.611 113.778 0.630
202212 0.598 114.548 0.612
202303 0.136 115.427 0.138
202306 0.054 115.647 0.055
202309 0.019 116.087 0.019
202312 0.012 117.296 0.012

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


China Biotech Services Holdings  (HKSE:08037) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

China Biotech Services Holdings's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.375/0.52
=0.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


China Biotech Services Holdings Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of China Biotech Services Holdings's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


China Biotech Services Holdings Business Description

Traded in Other Exchanges
N/A
Address
255-257 Gloucester Roaad, Suites 1904-05A, 19th Floor, Sino Plaza, Causeway Bay, Hong Kong, HKG
China Biotech Services Holdings Ltd is an investment holding company. It operates through six segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Securities, Insurance brokerage, BNCT and Others. It derives prime revenue from the Medical and health related services segment which involves the provision of medical laboratory testing and health check services. The group has a business presence in Hong Kong and the PRC, of which key revenue is generated from Hong Kong.
Executives
Liu Xiaolin 2101 Beneficial owner
Genius Earn Limited 2201 Interest of corporation controlled by you
Genius Lead Limited 2101 Beneficial owner
Guoyuan International Holdings Limited 2201 Interest of corporation controlled by you
Guoyuan Securities Co., Ltd. 2201 Interest of corporation controlled by you
Guoyuan Securities Investment (hong Kong) Limited 2101 Beneficial owner
Richlane Ventures Limited 2101 Beneficial owner
Ko Chun Shun, Johnson 2201 Interest of corporation controlled by you

China Biotech Services Holdings Headlines

No Headlines